These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 33950230)

  • 1. The safety of JAK-1 inhibitors.
    Clarke B; Yates M; Adas M; Bechman K; Galloway J
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii24-ii30. PubMed ID: 33950230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
    Mysler E; Lizarraga A
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of Jak 1 inhibitors for rheumatoid arthritis.
    Nash P
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii31-ii38. PubMed ID: 33950231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
    Avci AB; Feist E; Burmester GR
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
    Harigai M
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK1 selective inhibitors for the treatment of spondyloarthropathies.
    White JPE; Coates LC
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii39-ii44. PubMed ID: 33950224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
    Westhovens R
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis.
    Martinez-Molina C; Guardiola Tey JM; Ruiz-Ramos J; Feliu A; Puig-Campmany M; Vidal S; Corominas H
    Med Clin (Barc); 2024 Oct; 163(8):391-396. PubMed ID: 39003114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 15. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filgotinib for the treatment of rheumatoid arthritis.
    Taylor PC; Abdul Azeez M; Kiriakidis S
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
    Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Janus kinase inhibitors come of age.
    O'Shea JJ; Gadina M
    Nat Rev Rheumatol; 2019 Feb; 15(2):74-75. PubMed ID: 30622297
    [No Abstract]   [Full Text] [Related]  

  • 19. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review.
    Winthrop K; Isaacs J; Calabrese L; Mittal D; Desai S; Barry J; Strengholt S; Galloway J
    Semin Arthritis Rheum; 2023 Feb; 58():152120. PubMed ID: 36347212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgotinib in rheumatoid arthritis.
    Westhovens R
    Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.